News Releases

News Releases

Date Title
Jun 25, 2018
Summary ToggleOpiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Jun 12, 2018
Summary ToggleOpiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
Jun 04, 2018
Summary ToggleOpiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention
May 29, 2018
Summary ToggleOpiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual Meeting
May 08, 2018
Summary ToggleOpiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 03, 2018
Summary ToggleOpiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders
Apr 18, 2018
Summary ToggleOpiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Mar 19, 2018
Summary ToggleOpiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
Mar 07, 2018
Summary ToggleOpiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update
Feb 12, 2018
Summary ToggleOpiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Feb 08, 2018
Summary ToggleOpiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCANĀ® Nasal Spray for Opioid Overdose
Jan 02, 2018
Summary ToggleOpiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants